Efficacy and Safety of MEDI7352 in Participants with Painful Diabetic Neuropathy

Study identifier:D5680C00002

ClinicalTrials.gov identifier:NCT03755934

EudraCT identifier:2018-002523-42

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects with Painful Diabetic Neuropathy

Medical condition

Painful Diabetic Neuropathy

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI7352

Sex

All

Actual Enrollment

112

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 19 Nov 2018
Primary Completion Date: 29 Jun 2023
Study Completion Date: 29 Jun 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria